Do you want to read an article? Please log in or register.
High expression of GRP78/BiP as a novel predictor of favorable outcomes in patients with advanced thymic carcinoma
Related content
Endocrine and Neuroendocrine Tumors (NET)
Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial
Lancet Oncol.
Sato J, Satouchi M, Itoh S, Okuma Y, Niho S, Mizugaki H, Murakami H, Fujisaka Y, Kozuki T, Nakamura K, Nagasaka Y, Kawasaki M, Yamada T, Machida R, Kuchiba A, Ohe Y, Yamamoto N
doi: 10.1016/S1470-2045(20)30162-5.
RECOMMENDED
Genitourinary Cancer
Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial
Lancet Oncol.
Cella D, Grünwald V, Escudier B, Hammers HJ, George S, Nathan P, Grimm MO, Rini BI, Doan J, Ivanescu C, Paty J, Mekan S, Motzer RJ
doi: 10.1016/S1470
RECOMMENDED
Head and Neck Cancer
A Gene-Expression Predictor for Efficacy of Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma
★ 2
Recommended by
Alexander Meisel, Faculty Member
J Natl Cancer Inst.
Lei Y, Li YQ, Jiang W, Hong XH, Ge WX, Zhang Y, Hu WH, Wang YQ, Liang YL, Li JY, Cho WCS, Yun JP, Zeng J, Chen JW, Liu LZ, Li L, Chen L, Xie FY, Li WF, Mao YP, Liu X, Chen YP, Tang LL, Sun Y, Liu N, Ma J
doi: 10.1093/jnci/djaa100.Visit the original publication at ncbi.nlm.nih.gov
Genitourinary Cancer
Clinical characteristics, treatment outcomes and potential novel therapeutic options for patients with neuroendocrine carcinoma of the prostate
Oncotarget.
Apostolidis L, Nientiedt C, Winkler EC, Berger AK, Kratochwil C, Kaiser A, Becker AS, Jäger D, Hohenfellner M, Hüttenbrink C, Pahernik S, Distler FA, Grüllich C
doi: 10.18632/oncotarget.26523.
Lymphoma
A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts
Lancet Oncol.
Huet S, Tesson B, Jais JP, Feldman AL, Magnano L, Thomas E, Traverse-Glehen A, Albaud B, Carrère M, Xerri L, Ansell SM, Baseggio L, Reyes C, Tarte K, Boyault S, Haioun C, Link BK, Feugier P, Lopez-Guillermo A, Tilly H, Brice P, Hayette S, Jardin F, Offner F, Sujobert P, Gentien D, Viari A, Campo E, Cerhan JR, Salles G
doi: 10.1016/S1470-2045
Head and Neck CancerRadio-Oncology
Patterns of Treatment Failure and Postrecurrence Outcomes Among Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma After Chemoradiotherapy Using Modern Radiation Techniques
JAMA Oncol.
Leeman JE, Li JG, Pei X, Venigalla P, Zumsteg ZS, Katsoulakis E, Lupovitch E, McBride SM, Tsai CJ, Boyle JO, Roman BR, Morris LGT, Dunn LA, Sherman EJ, Lee NY, Riaz N
doi: 10.1001/
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
N Engl J Med.
Abou-Alfa GK, Meyer T, Cheng AL, El-Khoueiry AB, Rimassa L, Ryoo BY, Cicin I, Merle P, Chen Y, Park JW, Blanc JF, Bolondi L, Klümpen HJ, Chan SL, Zagonel V, Pressiani T, Ryu MH, Venook AP, Hessel C, Borgman-Hagey AE, Schwab G, Kelley RK
doi: 10.1056/NEJMoa1717002.
RECOMMENDED
Head and Neck Cancer
Comparing outcomes of concurrent chemotherapy regimens in patients 65 years old or older with locally advanced oropharyngeal carcinoma
Cancer.
Amini A, Eguchi M, Jones BL, Stokes WA, Gupta A, McDermott JD, Massarelli E, Bradley CJ, Karam SD
doi: 10.1002/cncr.31740.
Head and Neck Cancer
Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind, multicentre, randomised, phase 2 study
Lancet Oncol.
Sun XS, Tao Y, Le Tourneau C, Pointreau Y, Sire C, Kaminsky MC, Coutte A, Alfonsi M, Boisselier P, Martin L, Miroir J, Ramee JF, Delord JP, Clatot F, Rolland F, Villa J, Magne N, Elicin O, Gherga E, Nguyen F, Lafond C, Bera G, Calugaru V, Geoffrois L, Chauffert B, Zubel A, Zanna C, Brienza S, Crompton P, Rouits E, Gollmer K, Szyldergemajn S, Bourhis J
doi: 10.1016/S1470-2045(20)30327-2.